D L Kroetz
Overview
Explore the profile of D L Kroetz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chua K, Kroetz D
Clin Pharmacol Ther
. 2016 Dec;
101(4):450-452.
PMID: 27981569
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity experienced in 30-40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN...
2.
Li M, Seiser E, Baldwin R, Ramirez J, Ratain M, Innocenti F, et al.
Pharmacogenomics J
. 2016 Nov;
18(1):35-42.
PMID: 27845419
Neutropenia is a common dose-limiting toxicity associated with irinotecan treatment. Although UGT1A1 variants have been associated with neutropenia, a fraction of neutropenia risk remains unaccounted for. To identify additional genetic...
3.
4.
Yee S, Giacomini M, Hsueh C, Weitz D, Liang X, Goswami S, et al.
Clin Pharmacol Ther
. 2016 Jul;
100(5):524-536.
PMID: 27447836
Transporter-mediated drug-drug interactions (DDIs) are a major cause of drug toxicities. Using published genome-wide association studies (GWAS) of the human metabolome, we identified 20 metabolites associated with genetic variants in...
5.
Chhibber A, French C, Yee S, Gamazon E, Theusch E, Qin X, et al.
Pharmacogenomics J
. 2016 Feb;
17(2):137-145.
PMID: 26856248
Variation in the expression level and activity of genes involved in drug disposition and action ('pharmacogenes') can affect drug response and toxicity, especially when in tissues of pharmacological importance. Previous...
6.
7.
Martin M, Hoffman J, Freimuth R, Klein T, Dong B, Pirmohamed M, et al.
Clin Pharmacol Ther
. 2014 Feb;
95(5):499-500.
PMID: 24561393
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence...
8.
Chhibber A, Mefford J, Stahl E, Pendergrass S, Baldwin R, Owzar K, et al.
Pharmacogenomics J
. 2014 Feb;
14(4):336-42.
PMID: 24513692
Peripheral neuropathy is a common dose-limiting toxicity for patients treated with paclitaxel. For most individuals, there are no known risk factors that predispose patients to the adverse event, and pathogenesis...
9.
Markova S, Schwartz J, Kroetz D
Clin Pharmacol Ther
. 2013 Dec;
95(3):252.
PMID: 24346422
No abstract available.
10.
Markova S, De Marco T, Bendjilali N, Kobashigawa E, Mefford J, Sodhi J, et al.
Clin Pharmacol Ther
. 2013 Jul;
94(6):678-86.
PMID: 23863877
Bosentan (Tracleer) is an endothelin receptor antagonist prescribed for the treatment of pulmonary arterial hypertension (PAH). Its use is limited by drug-induced liver injury (DILI). To identify genetic markers of...